MyoKardia_Logo_RGB.png
New Insights on Disease Burden for Hypertrophic Cardiomyopathy Patients Published in Circulation
August 23, 2018 08:00 ET | MyoKardia, Inc.
HCM Patients at Greater Risks of Atrial Fibrillation, Heart Failure and Increased Mortality Younger Age of Diagnosis and Genetic Status Associated with Higher Rates of Long-term Complications and...
MyoKardia_Logo_RGB.png
MyoKardia Reports Second Quarter 2018 Financial Results
August 08, 2018 16:02 ET | MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of...
MyoKardia_Logo_RGB.png
MyoKardia to Present at the 2018 Wedbush Pacgrow Healthcare Conference
August 07, 2018 16:01 ET | MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
MyoKardia_Logo_RGB.png
MyoKardia to Report Second Quarter 2018 Financial Results on Wednesday, August 8, 2018
August 01, 2018 16:30 ET | MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
MyoKardia_Logo_RGB.png
MyoKardia Doses First Patient in Pivotal Phase 3 EXPLORER-HCM Trial of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy
June 26, 2018 08:30 ET | MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., June 26, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
MyoKardia_Logo_RGB.png
MyoKardia Announces Pricing of Public Offering of Common Stock
May 22, 2018 20:05 ET | MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., May 22, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
MyoKardia_Logo_RGB.png
MyoKardia Announces Proposed Public Offering of Common Stock
May 21, 2018 16:01 ET | MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., May 21, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
MyoKardia_Logo_RGB.png
MyoKardia Announces Design of Phase 3 EXPLORER-HCM Study Evaluating Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy
May 21, 2018 07:30 ET | MyoKardia, Inc.
Single Pivotal to Support Registration; Target Enrollment of 220 Patients; Primary Endpoint of Clinical Response Using Peak VO2 and NYHA Classification Improvements Expected to Initiate in Second...
MyoKardia_Logo_RGB.png
MyoKardia to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
May 10, 2018 16:30 ET | MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
MyoKardia_Logo_RGB.png
MyoKardia Doses First Patient in PIONEER Open-Label Extension Study of Mavacamten for Symptomatic, Obstructive Hypertrophic Cardiomyopathy
May 10, 2018 08:30 ET | MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...